Plasma Fractionation Market

Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) - Global Forecast to 2027

Report Code: BT 3042 May, 2022, by marketsandmarkets.com

[328 Pages Report] The global plasma fractionation market size is projected to reach USD 36.7 billion by 2027 from USD 26.5 billion in 2022, at a CAGR of 6.7% during the forecast period. Market growth is driven mainly by factors such as rising prevalence of bleeding disorders, increased risk of communicable diseases, and rise in geriatric population. However, stringent government regulations, and reduced supply of plasma due to low donor turnout are expected to restrain the growth of this market to a certain extent during the forecast period.

Plasma Fractionation Market

To know about the assumptions considered for the study, Request for Free Sample Report

COVID-19 impact on the Plasma Fractionation Market

Drivers and Opportunities

DRIVERS AND OPPORTUNITIES

STATISTICS

SHORT-TERM IMPACT
(2020–2022)

LONG-TERM IMPACT
(2020–2026)

Increased need for new therapies for COVID-19 treatment

Several established pharmaceutical and biopharmaceutical companies, as well as small startups, have stepped forward to develop treatments that target the infection caused by the novel coronavirus. Various key players operating in the plasma fractionation market collaborated together to form the ‘CoVIg-19 Plasma Alliance,’ an alliance to accelerate the development of plasma-derived hyperimmune globulin therapies for COVID-19. The alliance includes various key players of the plasma industry, such as Biotest, BPL, CSL, LFB, Octapharma, Takeda, ADMA Biologics, BioPharma Plasma, GC Pharma, Liminal BioSciences, and Sanquin.

(+)1.5 - (+)2.0

(+)2.0 – (+) 3.0

CUMULATIVE GROWTH FROM DRIVERS AND OPPORTUNITIES

 

(+)2.0 - (+)3.5

(+)1.0 – (+) 2.5

Restraints and Challenges


RESTRAINTS AND CHALLENGES

STATISTICS

SHORT-TERM IMPACT
(2020–2022)

LONG-TERM IMPACT
(2020–2026)

Low donor turnout for plasma

The COVID-19 pandemic caused lockdowns in various parts of the world, which resulted in low donor turnouts at plasma collection centers and created a shortfall of plasma for manufacturing plasma fractionation products.

(-)2.5% - (-) 3.5%

(-)1.5% - (-) 2.0%

CUMULATIVE DECLINE FROM RESTRAINTS AND CHALLENGES

 

(-)2.0% - (-)3.5%

(-)2.0% - (-) 1.5%

Source: Secondary Literature, Interviews with Experts, and MarketsandMarkets Analysis

MarketsandMarkets has considered the following scenarios to assess COVID-19 impact on the plasma fractionation market:

Short-term Impact: It indicates the impact scenario due to the impact of drivers/opportunities and restraints/challenges on market growth during 2020–2022. The market impact is expected to be in the range of 0.0%–1.0%.

Long-term Impact: The scenario caused by the impact of drivers/opportunities and restraints/challenges on market growth during 2020–2027. The market impact is expected to be in the range of 1.0%–3.0%.

Cumulative Growth Analysis

MARKET DYNAMICS

SHORT-TERM IMPACT (2020–2022)

LONG-TERM IMPACT (2020–2026)

Drivers and Opportunities

(+)2.0 - (+)3.5

(+)1.0 – (+) 2.5

Restraints and Challenges

(-)5.0% - (-)6.5%

(-)2.0% - (-) 1.5%

Projected Cumulative Growth

(-)0.0% - (-) 1.0%

(+)1.0% - (+) 3.0%

Source: Secondary Literature, Interviews with Experts, and MarketsandMarkets Analysis

Global Plasma fractionation Market Dynamics

DRIVER: Growing prevalence of respiratory diseases and AATD

In recent years, the use of protease inhibitors such as alpha-1-antitrypsin has increased significantly for the treatment of lung diseases (such as emphysema) and hepatic diseases (such as hepatic inflammation, fibrosis, and cirrhosis). Alpha-1-antitrypsin deficiency (AATD) is a chronic unrecognized metabolic genetic disorder. It is responsible for 2–3% of emphysema cases in the US. The deficiency of alpha-1-antitrypsin leads to the early onset of panlobular emphysema in both smokers and non-smokers, and the abnormal accumulation of alpha-1-antitrypsin in the liver leads to liver diseases. AATD occurs worldwide, but its prevalence varies by geography. According to the NIH, AATD affects about 1 in 1,500−3,500 individuals in European countries. On the other hand, the prevalence of AATD is low in the APAC region. About 10% of infants with alpha-1-antitrypsin deficiency develop liver diseases, and approximately 15% of adults with alpha-1-antitrypsin deficiency develop liver damage (cirrhosis) due to the formation of scar tissue in the liver.

Emphysema, along with chronic bronchitis, is collectively known as chronic obstructive pulmonary disease (COPD). According to the Global Impact of Respiratory Disease report of 2017 issued by the Forum of International Respiratory Societies, about 65 million people suffer from COPD and 3 million die from it every year, making it the third-leading cause of death worldwide. Moreover, about 2% of emphysema cases occur due to the hereditary deficiency of the alpha-1-antitrypsin gene. Also, chronic respiratory diseases pose a major public health problem, with an estimated 3.9 million deaths in 2017, accounting for 7% of all deaths worldwide.

The growing prevalence of AATD and emphysema and improvements in diagnostic techniques such as CT scanning are expected to increase the number of people undergoing therapies for these diseases. This, in turn, will lead to the greater demand for protease inhibitors such as alpha-1-antitrypsin and contribute to the overall growth of the plasma fractionation market.

RESTRAINT: Reduced supply of plasma due to low donor turnout

The COVID-19 pandemic negatively affected the number of blood donations carried out globally in 2020 and 2021. Plasma donation centers and blood donation centers witnessed a steep decline in the number of blood donors due to the lockdowns imposed worldwide. Despite effectively containing the virus, lockdowns and other stringent social distancing measures had a profound impact on health systems worldwide, including blood donation and supply as well as clinical transfusion management.

Stringent laboratory biosafety guidelines for SARS-CoV-2 were formulated by the World Health Organization and Clinical and Diagnostic Centers in the US, China, as well as in many other countries. Biosafety Level 3 protection was recommended for laboratory personnel encountering samples from suspected and confirmed cases of SARS-CoV-2, and instructions were given that biosafety protection measures were also to be performed to minimize the risk of virus spread. The waiting time after centrifugation was prolonged to reduce the risk of aerosol transmission, and extra steps were added to laboratory protocols, such as disinfection with 75% ethanol spraying and conducting manual procedures in biological safety cabinets. Such strict lab practices and increased precautions negatively impacted the supply of plasma fractionation products, thus creating a shortage of plasma products during the pandemic.

OPPORTUNITY: Rising prevalence of bleeding disorders

Hemophilia or hematology disorders form one of the major application areas of plasma fractionation products. Hemophilia is a hereditary bleeding disorder characterized by impaired blood coagulation due to deficiencies in the production or function of coagulation factor VIII. Hemophilia A affects 1 in 5,000 males. About 400 babies are born with hemophilia A each year. According to the World Federation of Hemophilia, the number of hemophilia patients worldwide was 167,110 in 2011, which increased by 25.9% to 210,454 in 2018. Only 30% of patients are actually diagnosed with hemophilia, and 25% of them receive treatment. The remaining remain undiagnosed, and nearly 75% of patients receive inadequate treatment or no treatment at all. However, the diagnosis and treatment rate of hemophilia is on the rise since the last decade.

The immunoglobins segment will witness the highest growth during the forecast period.

Based on product, the plasma fractionation market is segmented into immunoglobulins, coagulation factor concentrates, albumins, protease inhibitors, and other products. The immunoglobulins segment accounted for the largest share of the plasma fractionation market in 2021. This segment is also expected to register the highest CAGR during the forecast period. The large share of this segment is attributed various off-label indications of immunoglobulin, applications of these drugs. Immunoglobulins are also used to combat the effects of immunosenescence or age-related changes in immunity. With the growing prevalence of infections and disorders, the use of immunoglobulins is expected to increase in the coming years.

The neurology segment dominated the plasma fractionation market in 2021.

Based on application, the plasma fractionation market is segmented into neurology, immunology, hematology, critical care, pulmonology, hemato-oncology, rheumatology, and other applications. In 2021, the neurology segment accounted for the largest share of the plasma fractionation market. This is mainly due to the response of IVIg in a shorter period than steroids or oral immunosuppressants. IVIg is effective in a number of disorders of the peripheral and central nervous systems. IVIg is also being evaluated for other indications related to neurology, including Alzheimer’s disease. The positive results for these indications would increase the demand for IVIg in neurological applications.

Plasma Fractionation Market by Region

To know about the assumptions considered for the study, download the pdf brochure

North America was the largest regional market for plasma fractionation in 2021.

Geographically, the plasma fractionation market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2021, North America accounted for the largest share of the plasma fractionation market, followed by Europe and the Asia Pacific. The large share of North America in the global market is attributed to the increasing use of immunoglobulins in neurological and autoimmune diseases and the increasing use of prophylactic treatments among diagnosed patients. The high number of registered hemophilic patients also propels the growth of this market. The growing number of hemophilic patients will increase the adoption of coagulation factors, which, in turn, will drive the market for plasma fractionation in North America.

Key Market Players

Key players in the global plasma fractionation market include CSL (Australia), Grifols, S.A. (Spain), Shire (US), Octapharma AG (Switzerland), Kedrion S.P.A (Italy), LFB (France), Biotest AG (Germany), Sanquin (Netherlands), China Biologic Products Holdings Inc. (China), GC Pharma (Korea), Bio Products Ltd. (UK), Japan Blood Products Organization (Japan), Emergent BioSolutions (US), Shanghai Raas Blood Products Co., Ltd. (China), Intas Pharmaceuticals Ltd. (India), Bharat Serum Vaccines Limited (India), SK Plasma (Korea), Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (China), KabaFusion (US), Centurion Pharma (Istanbul), ADMA Biologics, Inc. (US), PlasmaGen BioSciences Pvt. Ltd. (India), Virchow Biotech Private Limited (India), Fusion Healthcare (India), and Hemarus Therapeutics Limited (India).

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

Report Metric

Details

Market size available for years

2020–2027

Base year considered

2021

Forecast period

2022–2027

Forecast units

Value (USD)

Segments covered

Product, end user, and region

Geographies covered

North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa

Companies covered

CSL (Australia), Grifols, S.A. (Spain), Shire (US), Octapharma AG (Switzerland), Kedrion S.P.A (Italy), LFB (France), Biotest AG (Germany), Sanquin (Netherlands), China Biologic Products Holdings Inc. (China), GC Pharma (Korea), Bio Products Ltd. (UK), Japan Blood Products Organization (Japan), Emergent BioSolutions (US), Shanghai Raas Blood Products Co., Ltd. (China), Intas Pharmaceuticals Ltd. (India), Bharat Serum Vaccines Limited (India), SK Plasma (Korea), Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (China), KabaFusion (US), Centurion Pharma (Istanbul), ADMA Biologics, Inc. (US), PlasmaGen BioSciences Pvt. Ltd. (India), Virchow Biotech Private Limited (India), Fusion Healthcare (India), and Hemarus Therapeutics Limited (India)

This report categorizes the plasma fractionation market into the following segments and subsegments:

By Product

  • Immunoglobulins
    • Intravenous Immunoglobulins
    • Subcutaneous Immunoglobulins
    • Other Immunoglobulins
  • Coagulation Factor Concentrates
    • Factor VIII
    • Factor IX
    • Von Willebrand Factor
    • Prothrombin Complex Concentrate
    • Fibrinogen Concentrates
    • Factor XIII
  • Albumin
  • Protease Inhibitors
  • Other Products
    • Factor XI

By Application

  • Neurology
  • Immunology
  • Hematology
  • Critical care
  • Pulmonology
  • Hemato-oncology
  • Rheumatology
  • Other Applications

By End User

  • Hospitals & Clinics
  • Clinical Research Laboratories
  • Academic Institutes

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • UK
    • RoE
  • Asia Pacific
    • China
    • Japan
    • Australia
    • India
    • Vietnam
    • Indonesia
    • Malaysia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • RoLATAM
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • Egypt
    • UAE
    • Rest of Middle East and Africa

Recent Developments

  • In March 2022, Grifols (Spain) received European approvals for XEMBIFY, a 20% subcutaneous immunoglobulin (SCIG)
  • In January 2022, Permira, a global investment firm, announced that it will be acquiring Kedrion and merging the company with BPL.
  • In August 2021, CSL (Australia) Received FDA approval for the new BERINERT [C1 Esterase inhibitor, Human (Intravenous)] Administration Kit for improved patient convenience.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 29)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS & EXCLUSIONS
    1.3 MARKET SCOPE
                    FIGURE 1 PLASMA FRACTIONATION MARKET
           1.3.1 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY
    1.5 LIMITATIONS
    1.6 STAKEHOLDERS
    1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 33)
    2.1 RESEARCH DATA
           FIGURE 2 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
                    FIGURE 3 BREAKDOWN OF PRIMARIES BY RESPONDENT, DESIGNATION, AND REGION: PLASMA FRACTIONATION MARKET
    2.2 MARKET ESTIMATION METHODOLOGY
           FIGURE 4 PLASMA FRACTIONATION MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2021
           FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2021
           2.2.1 INSIGHTS FROM PRIMARY EXPERTS
                    FIGURE 6 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
    2.3 MARKET GROWTH RATE PROJECTIONS
           FIGURE 7 PLASMA FRACTIONATION MARKET (SUPPLY SIDE): CAGR PROJECTIONS
           FIGURE 8 PLASMA FRACTIONATION MARKET (DEMAND SIDE): GROWTH ANALYSIS OF DEMAND-SIDE FACTORS
           2.3.1 DATA TRIANGULATION
                    FIGURE 9 DATA TRIANGULATION METHODOLOGY
    2.4 RESEARCH ASSUMPTIONS
           2.4.1 COVID-19 ASSUMPTIONS
    2.5 RISK ANALYSIS

3 EXECUTIVE SUMMARY (Page No. - 44)
    FIGURE 10 PLASMA FRACTIONATION MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)
    FIGURE 11 PLASMA FRACTIONATION MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
    FIGURE 12 PLASMA FRACTIONATION MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
    FIGURE 13 GEOGRAPHICAL SNAPSHOT OF THE PLASMA FRACTIONATION MARKET

4 PREMIUM INSIGHTS (Page No. - 47)
    4.1 PLASMA FRACTIONATION MARKET OVERVIEW
           FIGURE 14 GROWING USE OF IMMUNOGLOBULINS IN VARIOUS THERAPEUTIC AREAS IS THE MAJOR FACTOR DRIVING MARKET GROWTH
    4.2 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY PRODUCT & COUNTRY (2019)
           FIGURE 15 IMMUNOGLOBULINS ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN PLASMA FRACTIONATION MARKET IN 2021
    4.3 PLASMA FRACTIONATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
           FIGURE 16 GERMANY TO REGISTER THE HIGHEST CAGR IN THE PLASMA FRACTIONATION MARKET DURING THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 50)
    5.1 INTRODUCTION
           5.1.1 MARKET DYNAMICS
                    FIGURE 17 PLASMA FRACTIONATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    5.2 MARKET DYNAMICS
           TABLE 1 PLASMA FRACTIONATION MARKET: IMPACT ANALYSIS
           5.2.1 MARKET DRIVERS
                    5.2.1.1 Growing use of immunoglobulins in various therapeutic areas
                               TABLE 2 ON-LABEL AND OFF-LABEL INDICATIONS OF IVIG
                               TABLE 3 NUMBER OF CLINICAL STUDIES ON IMMUNOGLOBULINS, BY REGION (AS OF 2020–2021)
                               TABLE 4 NUMBER OF PATIENTS TREATED FOR TOP 15 TARGET CONDITIONS IN THE UK
                    5.2.1.2 Rapidly growing geriatric population
                               TABLE 5 GERIATRIC POPULATION, BY REGION, 2000−2050
                    5.2.1.3 Growing prevalence of respiratory diseases and AATD
                    5.2.1.4 New indications for plasma products
           5.2.2 MARKET RESTRAINTS
                    5.2.2.1 High costs and limited reimbursements
                    5.2.2.2 Market disruption caused by recombinant alternatives
           5.2.3 MARKET OPPORTUNITIES
                    5.2.3.1 Increased risk of communicable diseases
                    5.2.3.2 Rising prevalence of bleeding disorders
                               FIGURE 18 NUMBER OF HEMOPHILIA A AND HEMOPHILIA B PATIENTS WORLDWIDE, 2012–2018
                               TABLE 6 NUMBER OF HEMOPHILIA PATIENTS IN DEVELOPED AND EMERGING COUNTRIES, 2016 VS. 2018
           5.2.4 MARKET CHALLENGES
                    5.2.4.1 Reduced supply of plasma due to low donor turnout
                    5.2.4.2 Stringent government regulations
    5.3 IMPACT ASSESSMENT OF PLASMA FRACTIONATION MARKET
           FIGURE 19 SPECTRUM OF SCENARIOS BASED ON THE IMPACT OF UNCERTAINTIES ON THE GROWTH OF THE PLASMA FRACTIONATION MARKET
    5.4 PRICING ANALYSIS
           TABLE 7 AVERAGE SELLING PRICE OF PLASMA FRACTIONATION PRODUCTS, BY KEY PLAYER, 2021 (USD)
           TABLE 8 AVERAGE SELLING PRICE OF PLASMA FRACTIONATION PRODUCTS, BY REGION, 2021 (USD)
    5.5 IMPACT OF COVID-19 ON MARKET DYNAMICS
           5.5.1 DRIVERS AND OPPORTUNITIES
           5.5.2 RESTRAINTS AND CHALLENGES
           5.5.3 CUMULATIVE GROWTH ANALYSIS
    5.6 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
           FIGURE 20 REVENUE SHIFT & NEW POCKETS FOR PLASMA FRACTIONATION PRODUCT PROVIDERS
    5.7 VALUE CHAIN ANALYSIS
           FIGURE 21 PROCEDURE OF PLASMA FRACTIONATION
           FIGURE 22 VALUE CHAIN ANALYSIS OF THE PLASMA FRACTIONATION MARKET
    5.8 SUPPLY CHAIN ANALYSIS
           FIGURE 23 SUPPLY CHAIN ANALYSIS OF THE PLASMA FRACTIONATION MARKET
    5.9 ECOSYSTEM ANALYSIS
           FIGURE 24 ECOSYSTEM ANALYSIS OF THE PLASMA FRACTIONATION MARKET
           TABLE 9 SUPPLY CHAIN ECOSYSTEM
    5.10 PATENT ANALYSIS
           FIGURE 25 PATENT APPLICATIONS FOR THE PLASMA FRACTIONATION MARKET, JANUARY 2012–MARCH 2022
           TABLE 10 INDICATIVE LIST OF PATENTS IN THE PLASMA FRACTIONATION MARKET
    5.11 KEY CONFERENCES AND EVENTS IN 2022–2023
                    TABLE 11 PLASMA FRACTIONATION MARKET: LIST OF CONFERENCES AND EVENTS
    5.12 REGULATORY ANALYSIS
           5.12.1 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS IN DIFFERENT REGIONS/COUNTRIES
           5.12.2 REGULATORY SCENARIO IN DIFFERENT REGIONS/COUNTRIES
    5.13 PORTER’S FIVE FORCES ANALYSIS
                    TABLE 12 PLASMA FRACTIONATION MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.13.1 THREAT FROM NEW ENTRANTS
           5.13.2 THREAT FROM SUBSTITUTES
           5.13.3 BARGAINING POWER OF BUYERS
           5.13.4 BARGAINING POWER OF SUPPLIERS
           5.13.5 DEGREE OF COMPETITION
    5.14 TECHNOLOGY ANALYSIS
           5.14.1 COHN’S COLD ETHANOL PLASMA FRACTIONATION
           5.14.2 GEL FILTRATION PLASMA FRACTIONATION
           5.14.3 HUMAN PLASMA FRACTIONATION BY POLYETHYLENE GLYCOL
           5.14.4 PLASMA FRACTIONATION BY AMMONIUM SULFATE
    5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
                    FIGURE 26 INFLUENCE OF STAKEHOLDERS IN THE BUYING PROCESS FOR PLASMA FRACTIONATION PRODUCTS
    5.16 KEY BUYING CRITERIA BY END USERS
                    FIGURE 27 BUYING CRITERIA OF END USERS

6 PLASMA FRACTIONATION MARKET, BY PRODUCT (Page No. - 81)
    6.1 INTRODUCTION
           TABLE 13 PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
    6.2 IMMUNOGLOBULINS
           TABLE 14 IVIG VS. SCIG THERAPY
           TABLE 15 PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY REGION, 2020–2027 (USD MILLION)
           TABLE 16 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
           TABLE 17 EUROPE: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
           TABLE 18 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
           TABLE 19 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
           TABLE 20 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
           TABLE 21 PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
           6.2.1 INTRAVENOUS IMMUNOGLOBULINS
                    6.2.1.1 IVIg holds the largest share of the immunoglobulins market
                               TABLE 22 INTRAVENOUS IMMUNOGLOBULINS OFFERED BY KEY MARKET PLAYERS
                               TABLE 23 PLASMA FRACTIONATION MARKET FOR INTRAVENOUS IMMUNOGLOBULINS, BY REGION, 2020–2027 (USD MILLION)
                               TABLE 24 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR INTRAVENOUS IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
                               TABLE 25 EUROPE: PLASMA FRACTIONATION MARKET FOR INTRAVENOUS IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
                               TABLE 26 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR INTRAVENOUS IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
                               TABLE 27 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR INTRAVENOUS IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
                               TABLE 28 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR INTRAVENOUS IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
           6.2.2 SUBCUTANEOUS IMMUNOGLOBULINS
                    6.2.2.1 Benefits of self-administration and lower incidence of non-serious systemic adverse reactions will drive the growth of the SCIg market
                               TABLE 29 SUBCUTANEOUS IMMUNOGLOBULINS OFFERED BY KEY MARKET PLAYERS
                               TABLE 30 PLASMA FRACTIONATION MARKET FOR SUBCUTANEOUS IMMUNOGLOBULINS, BY REGION, 2020–2027 (USD MILLION)
                               TABLE 31 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR SUBCUTANEOUS IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
                               TABLE 32 EUROPE: PLASMA FRACTIONATION MARKET FOR SUBCUTANEOUS IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
                               TABLE 33 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR SUBCUTANEOUS IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
                               TABLE 34 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR SUBCUTANEOUS IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
                               TABLE 35 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR SUBCUTANEOUS IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
           6.2.3 OTHER IMMUNOGLOBULINS
                    TABLE 36 OTHER IMMUNOGLOBULINS OFFERED BY KEY MARKET PLAYERS
                    TABLE 37 PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 38 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 39 EUROPE: PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 40 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 41 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 42 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR OTHER IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
    6.3 COAGULATION FACTOR CONCENTRATES
           TABLE 43 PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY REGION, 2020–2027 (USD MILLION)
           TABLE 44 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)
           TABLE 45 EUROPE: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)
           TABLE 46 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)
           TABLE 47 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)
           TABLE 48 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)
           TABLE 49 PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
           6.3.1 FACTOR VIII
                    6.3.1.1 Factor VIII holds the largest share of the coagulation factor concentrates market
                               TABLE 50 FACTOR VIII OFFERED BY KEY MARKET PLAYERS
                               TABLE 51 PLASMA FRACTIONATION MARKET FOR FACTOR VIII, BY REGION, 2020–2027 (USD MILLION)
                               TABLE 52 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR VIII, BY COUNTRY, 2020–2027 (USD MILLION)
                               TABLE 53 EUROPE: PLASMA FRACTIONATION MARKET FOR FACTOR VIII, BY COUNTRY, 2020–2027 (USD MILLION)
                               TABLE 54 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR FACTOR VIII, BY COUNTRY, 2020–2027 (USD MILLION)
                               TABLE 55 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR VIII, BY COUNTRY, 2020–2027 (USD MILLION)
                               TABLE 56 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR FACTOR VIII, BY COUNTRY, 2020–2027 (USD MILLION)
           6.3.2 FACTOR IX
                    6.3.2.1 Rising number of hemophilic patients to drive the growth of this market
                               TABLE 57 FACTOR IX OFFERED BY KEY MARKET PLAYERS
                               TABLE 58 PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY REGION, 2020–2027 (USD MILLION)
                               TABLE 59 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY COUNTRY, 2020–2027 (USD MILLION)
                               TABLE 60 EUROPE: PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY COUNTRY, 2020–2027 (USD MILLION)
                               TABLE 61 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY COUNTRY, 2020–2027 (USD MILLION)
                               TABLE 62 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY COUNTRY, 2020–2027 (USD MILLION)
                               TABLE 63 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR FACTOR IX, BY COUNTRY, 2020–2027 (USD MILLION)
           6.3.3 VON WILLEBRAND FACTOR
                    6.3.3.1 Market growth is primarily driven by the increasing prevalence and diagnosis of Von Willebrand disease and hemophilia
                               TABLE 64 VON WILLEBRAND FACTOR OFFERED BY KEY MARKET PLAYERS
                               TABLE 65 PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY REGION, 2020–2027 (USD MILLION)
                               TABLE 66 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY COUNTRY, 2020–2027 (USD MILLION)
                               TABLE 67 EUROPE: PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY COUNTRY, 2020–2027 (USD MILLION)
                               TABLE 68 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY COUNTRY, 2020–2027 (USD MILLION)
                               TABLE 69 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY COUNTRY, 2020–2027 (USD MILLION)
                               TABLE 70 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR VON WILLEBRAND FACTOR, BY COUNTRY, 2020–2027 (USD MILLION)
           6.3.4 PROTHROMBIN COMPLEX CONCENTRATES
                    6.3.4.1 Advantages of PCC over fresh frozen plasma will support market growth in this segment
                               TABLE 71 PROTHROMBIN COMPLEX CONCENTRATES OFFERED BY KEY MARKET PLAYERS
                               TABLE 72 PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY REGION, 2020–2027 (USD MILLION)
                               TABLE 73 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)
                               TABLE 74 EUROPE: PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)
                               TABLE 75 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)
                               TABLE 76 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)
                               TABLE 77 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)
           6.3.5 FIBRINOGEN CONCENTRATES
                    6.3.5.1 Safety profile, accuracy, and speed of administration are the key advantages of fibrinogen concentrates
                               TABLE 78 FIBRINOGEN CONCENTRATES OFFERED BY KEY MARKET PLAYERS
                               TABLE 79 PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY REGION, 2020–2027 (USD MILLION)
                               TABLE 80 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)
                               TABLE 81 EUROPE: PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)
                               TABLE 82 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)
                               TABLE 83 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)
                               TABLE 84 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR FIBRINOGEN CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)
           6.3.6 FACTOR XIII
                    6.3.6.1 Applications in treating rare bleeding disorders will contribute to the demand for factor XIII
                               TABLE 85 FACTOR XIII OFFERED BY KEY MARKET PLAYERS
                               TABLE 86 PLASMA FRACTIONATION MARKET FOR FACTOR XIII, BY REGION, 2020–2027 (USD MILLION)
                               TABLE 87 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR XIII, BY COUNTRY, 2020–2027 (USD MILLION)
                               TABLE 88 EUROPE: PLASMA FRACTIONATION MARKET FOR FACTOR XIII, BY COUNTRY, 2020–2027 (USD MILLION)
                               TABLE 89 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR FACTOR XIII, BY COUNTRY, 2020–2027 (USD MILLION)
                               TABLE 90 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR XIII, BY COUNTRY, 2020–2027 (USD MILLION)
                               TABLE 91 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR FACTOR XIII, BY COUNTRY, 2020–2027 (USD MILLION)
           6.3.7 FACTOR XI
                    6.3.7.1 Growing demand for factor XI to treat bleeding disorders in patients to drive growth
                               TABLE 92 PLASMA FRACTIONATION MARKET FOR FACTOR XI, BY REGION, 2020–2027 (USD MILLION)
                               TABLE 93 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR XI, BY COUNTRY, 2020–2027 (USD MILLION)
                               TABLE 94 EUROPE: PLASMA FRACTIONATION MARKET FOR FACTOR XI, BY COUNTRY, 2020–2027 (USD MILLION)
                               TABLE 95 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR FACTOR XI, BY COUNTRY, 2020–2027 (USD MILLION)
                               TABLE 96 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR FACTOR XI, BY COUNTRY, 2020–2027 (USD MILLION)
                               TABLE 97 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR FACTOR XI, BY COUNTRY, 2020–2027 (USD MILLION)
    6.4 ALBUMIN
           6.4.1 RISING DEMAND FOR ALBUMIN AS AN ANTIOXIDANT TO DRIVE MARKET GROWTH
                    TABLE 98 ALBUMIN OFFERED BY KEY MARKET PLAYERS
                    TABLE 99 PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 100 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 101 EUROPE: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 102 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 103 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 104 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2020–2027 (USD MILLION)
    6.5 PROTEASE INHIBITORS
           6.5.1 RISING PREVALENCE OF COPD WILL DRIVE THE DEMAND FOR PROTEASE INHIBITORS
                    TABLE 105 PROTEASE INHIBITORS OFFERED BY KEY MARKET PLAYERS
                    TABLE 106 PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 107 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 108 EUROPE: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 109 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 110 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 111 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2020–2027 (USD MILLION)
    6.6 OTHER PLASMA PRODUCTS
                    TABLE 112 PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 113 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 114 EUROPE: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 115 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 116 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 117 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION)

7 PLASMA FRACTIONATION MARKET, BY APPLICATION (Page No. - 128)
    7.1 INTRODUCTION
           TABLE 118 PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
    7.2 NEUROLOGY
           7.2.1 RISING PREVALENCE OF MAJOR AGE-RELATED NEUROLOGICAL DISORDERS TO DRIVE MARKET GROWTH
                    TABLE 119 NUMBER OF DALYS FOR NEUROLOGICAL DISORDERS AND THE PERCENTAGE OF DALYS PROJECTED FOR 2005, 2015, AND 2030
                    TABLE 120 PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN NEUROLOGY
                    TABLE 121 PLASMA FRACTIONATION MARKET FOR NEUROLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 122 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR NEUROLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 123 EUROPE: PLASMA FRACTIONATION MARKET FOR NEUROLOGY APPLICATIONS, 2020–2027 (USD MILLION)
                    TABLE 124 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR NEUROLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 125 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR NEUROLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 126 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR NEUROLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
    7.3 IMMUNOLOGY
           7.3.1 INCREASING PREVALENCE OF IMMUNODEFICIENCY DISORDERS AMONG CHILDREN AND ADULTS WILL DRIVE THE GROWTH OF THIS MARKET
                    TABLE 127 LIST OF FDA-APPROVED INDICATIONS FOR IMMUNOGLOBULINS IN IMMUNOLOGY
                    TABLE 128 DIAGNOSIS DISTRIBUTION OF DIFFERENT CATEGORIES OF PRIMARY IMMUNODEFICIENCY DISEASE
                    TABLE 129 PREVALENCE OF PRIMARY IMMUNODEFICIENCY DISEASE, BY REGION, 2013 VS. 2015
                    TABLE 130 PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN IMMUNOLOGY
                    TABLE 131 PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 132 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 133 EUROPE: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY APPLICATIONS, 2020–2027 (USD MILLION)
                    TABLE 134 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 135 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 136 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
    7.4 HEMATOLOGY
           7.4.1 GROWTH IN THE NUMBER OF HEMOPHILIA PATIENTS TO DRIVE THE DEMAND FOR COAGULATION FACTOR CONCENTRATES AND IMMUNOGLOBULINS
                    TABLE 137 NUMBER OF HEMOPHILIA PATIENTS (2012–2020)
                    TABLE 138 PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN HEMATOLOGY
                    TABLE 139 PLASMA FRACTIONATION MARKET FOR HEMATOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 140 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 141 EUROPE: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY APPLICATIONS, 2020–2027 (USD MILLION)
                    TABLE 142 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 143 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 144 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
    7.5 CRITICAL CARE
           7.5.1 INCREASING OFF-LABEL USE OF ALBUMIN AND RISING USE OF ANTICOAGULANTS TO DRIVE THE DEMAND FOR PLASMA-DERIVED CRITICAL CARE PRODUCTS
                    TABLE 145 PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN CRITICAL CARE
                    TABLE 146 PLASMA FRACTIONATION MARKET FOR CRITICAL CARE APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 147 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 148 EUROPE: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE APPLICATIONS, 2020–2027 (USD MILLION)
                    TABLE 149 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 150 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 151 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
    7.6 PULMONOLOGY
           7.6.1 RISING PREVALENCE OF ALPHA-1-ANTITRYPSIN DEFICIENCY AND COPD TO DRIVE THE PLASMA FRACTIONATION MARKET FOR PULMONOLOGY
                    TABLE 152 PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN PULMONOLOGY
                    TABLE 153 PLASMA FRACTIONATION MARKET FOR PULMONOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 154 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 155 EUROPE: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY APPLICATIONS, 2020–2027 (USD MILLION)
                    TABLE 156 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 157 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 158 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
    7.7 HEMATO-ONCOLOGY
           7.7.1 RISING NUMBER OF BLOOD CANCER PATIENTS TO DRIVE THE DEMAND FOR PLASMA-DERIVED PRODUCTS
                    TABLE 159 INCIDENCE OF LEUKEMIA, MULTIPLE MYELOMA, AND HODGKIN’S LYMPHOMA, BY REGION, 2012−2018
                    TABLE 160 PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN HEMATO-ONCOLOGY
                    TABLE 161 PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 162 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 163 EUROPE: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY APPLICATIONS, 2020–2027 (USD MILLION)
                    TABLE 164 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 165 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 166 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                    7.8 RHEUMATOLOGY
           7.8.1 INCREASING PREVALENCE OF RHEUMATIC CONDITIONS TO DRIVE THE PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY
                    TABLE 167 PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 168 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 169 EUROPE: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY APPLICATIONS, 2020–2027 (USD MILLION)
                    TABLE 170 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 171 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 172 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
    7.9 OTHER APPLICATIONS
           TABLE 173 PLASMA-DERIVED PRODUCTS FOR OTHER APPLICATIONS
           TABLE 174 PLASMA FRACTIONATION MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
           TABLE 175 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
           TABLE 176 EUROPE: PLASMA FRACTIONATION MARKET FOR OTHER APPLICATIONS, 2020–2027 (USD MILLION)
           TABLE 177 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
           TABLE 178 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
           TABLE 179 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)

8 PLASMA FRACTIONATION MARKET, BY END USER (Page No. - 156)
    8.1 INTRODUCTION
           TABLE 180 PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
    8.2 HOSPITALS & CLINICS
           8.2.1 IMPROVING HEALTHCARE INFRASTRUCTURE AND GROWING NUMBER OF HOSPITALS & CLINICS—KEY FACTORS DRIVING GROWTH
                    TABLE 181 PLASMA FRACTIONATION MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 182 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 183 EUROPE: PLASMA FRACTIONATION MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 184 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 185 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR HOSPITALS & CLINICS, 2020–2027 (USD MILLION)
                    TABLE 186 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2020–2027 (USD MILLION)
    8.3 CLINICAL RESEARCH LABORATORIES
           8.3.1 INCREASING NUMBER OF CLINICAL STUDIES ON NEW THERAPEUTIC INDICATIONS FOR PLASMA-DERIVED PRODUCTS TO DRIVE MARKET GROWTH
                    TABLE 187 PLASMA FRACTIONATION MARKET FOR CLINICAL RESEARCH LABORATORIES, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 188 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR CLINICAL RESEARCH LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 189 EUROPE: PLASMA FRACTIONATION MARKET FOR CLINICAL RESEARCH LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 190 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR CLINICAL RESEARCH LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 191 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR CLINICAL RESEARCH LABORATORIES, 2020–2027 (USD MILLION)
                    TABLE 192 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR CLINICAL RESEARCH LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION)
    8.4 ACADEMIC INSTITUTES
           8.4.1 GROWING DEMAND FOR NEW DRUG MOLECULES TO DRIVE THE DEMAND FOR PLASMA PRODUCTS IN ACADEMIC INSTITUTES
                    TABLE 193 PLASMA FRACTIONATION MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 194 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 195 EUROPE: PLASMA FRACTIONATION MARKET FOR ACADEMIC INSTITUTES, 2020–2027 (USD MILLION)
                    TABLE 196 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 197 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR ACADEMIC INSTITUTES BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 198 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)

9 PLASMA FRACTIONATION MARKET, BY REGION (Page No. - 166)
    9.1 INTRODUCTION
           TABLE 199 PLASMA FRACTIONATION MARKET, BY REGION, 2020–2027 (USD MILLION)
    9.2 NORTH AMERICA
           FIGURE 28 NORTH AMERICA: PLASMA FRACTIONATION MARKET SNAPSHOT
           TABLE 200 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           TABLE 201 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
           TABLE 202 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
           TABLE 203 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
           TABLE 204 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
           TABLE 205 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.2.1 US
                    9.2.1.1 The US is the largest market for plasma fractionation products
                               TABLE 206 US: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                               TABLE 207 US: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 208 US: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 209 US: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                               TABLE 210 US: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.2.2 CANADA
                    9.2.2.1 Canada is one of the world’s highest per capita users of IVIg—a key factor driving market growth
                               TABLE 211 CANADA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                               TABLE 212 CANADA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 213 CANADA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 214 CANADA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                               TABLE 215 CANADA: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
    9.3 EUROPE
           TABLE 216 EUROPE: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           TABLE 217 EUROPE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
           TABLE 218 EUROPE: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
           TABLE 219 EUROPE: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
           TABLE 220 EUROPE: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
           TABLE 221 EUROPE: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.3.1 GERMANY
                    9.3.1.1 Germany has the highest plasma fractionation capacity in Europe
                               TABLE 222 GERMANY: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                               TABLE 223 GERMANY: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 224 GERMANY: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 225 GERMANY: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                               TABLE 226 GERMANY: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.3.2 UK
                    9.3.2.1 Increasing incidence of hemophilia and the growing consumption of coagulation factors to drive market growth in the UK
                               TABLE 227 UK: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                               TABLE 228 UK: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 229 UK: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 230 UK: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                               TABLE 231 UK: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.3.3 FRANCE
                    9.3.3.1 High prevalence of bleeding disorders to drive the market for plasma fractionation in France
                               TABLE 232 NUMBER OF PEOPLE WITH BLEEDING DISORDERS IN FRANCE, 2012–2020
                               TABLE 233 FRANCE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                               TABLE 234 FRANCE: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 235 FRANCE: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 236 FRANCE: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                               TABLE 237 FRANCE: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.3.4 ITALY
                    9.3.4.1 Growth in the country’s geriatric population drives the market for plasma fractionation
                               TABLE 238 PRODUCTION OF PLASMA PRODUCTS IN ITALY (2013, 2018, AND 2023-E)
                               TABLE 239 ITALY: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                               TABLE 240 ITALY: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 241 ITALY: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 242 ITALY: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                               TABLE 243 ITALY: PLASMA FRACTIONATION MARKET, BY END USER,  2020–2027 (USD MILLION)
           9.3.5 SPAIN
                    9.3.5.1 Growing demand for plasma products for the treatment of chronic diseases in the elderly is the key factor driving market growth
                               TABLE 244 SPAIN: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                               TABLE 245 SPAIN: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 246 SPAIN: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 247 SPAIN: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                               TABLE 248 SPAIN: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.3.6 REST OF EUROPE
                    TABLE 249 ROE: NUMBER OF HEMOPHILIA PATIENTS, BY COUNTRY, 2012–2018
                    TABLE 250 ROE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                    TABLE 251 ROE: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 252 ROE: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 253 ROE: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                    TABLE 254 ROE: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
    9.4 ASIA PACIFIC
           FIGURE 29 APAC: PLASMA FRACTIONATION MARKET SNAPSHOT
           TABLE 255 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           TABLE 256 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
           TABLE 257 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
           TABLE 258 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
           TABLE 259 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
           TABLE 260 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.4.1 CHINA
                    9.4.1.1 Rising incidence of diseases such as liver cancer and hepatitis B to drive market growth in China
                               TABLE 261 CHINA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                               TABLE 262 CHINA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 263 CHINA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 264 CHINA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                               TABLE 265 CHINA: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.4.2 JAPAN
                    9.4.2.1 Rising prevalence of neurological disorders and hematological diseases will support market growth in the country
                               TABLE 266 MEAN PER CAPITA FACTOR VIII AND IX USE IN JAPAN, 2014 VS. 2018 (IN IU/TOTAL POPULATION)
                               TABLE 267 PATIENTS WITH BLEEDING DISORDERS IN JAPAN, 2014 VS. 2020
                               TABLE 268 JAPAN: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                               TABLE 269 JAPAN: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 270 JAPAN: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 271 JAPAN: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                               TABLE 272 JAPAN: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.4.3 AUSTRALIA
                    9.4.3.1 Growing demand for plasma products for the treatment of chronic diseases to drive market growth
                               TABLE 273 TOTAL IG (GRAMS) USED IN AUSTRALIA, 2008/09–2017/18
                               TABLE 274 AUSTRALIAN GOVERNMENT FUNDING FOR THE SUPPLY OF BLOOD AND BLOOD PRODUCTS, 2008–2018 (USD MILLION)
                               TABLE 275 AUSTRALIA: BLOOD SECTOR OVERVIEW (2017–2018)
                               TABLE 276 AUSTRALIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                               TABLE 277 AUSTRALIA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 278 AUSTRALIA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 279 AUSTRALIA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                               TABLE 280 AUSTRALIA: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.4.4 INDIA
                    9.4.4.1 Growing healthcare awareness, availability of better diagnostic tools, and the rising geriatric population to drive market growth
                               TABLE 281 INDIA: NUMBER OF PATIENTS WITH BLEEDING DISORDERS, 2012–2018
                               TABLE 282 INDIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                               TABLE 283 INDIA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 284 INDIA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 285 INDIA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                               TABLE 286 INDIA: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.4.5 VIETNAM
                    9.4.5.1 Growing pool of patients suffering from COPD, PID, and bleeding disorders to drive market growth
                               TABLE 287 VIETNAM: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                               TABLE 288 VIETNAM: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 289 VIETNAM: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 290 VIETNAM: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                               TABLE 291 VIETNAM: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.4.6 INDONESIA
                    9.4.6.1 Growing government initiatives to drive market growth
                               TABLE 292 INDONESIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                               TABLE 293 INDONESIA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 294 INDONESIA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 295 INDONESIA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                               TABLE 296 INDONESIA: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.4.7 MALAYSIA
                    9.4.7.1 Increasing prevalence of bleeding disorders will support the plasma fractionation market in Malaysia
                               TABLE 297 MALAYSIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                               TABLE 298 MALAYSIA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 299 MALAYSIA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 300 MALAYSIA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                               TABLE 301 MALAYSIA: PLASMA FRACTIONATION MARKET, BY END USER,  2020–2027 (USD MILLION)
           9.4.8 REST OF ASIA PACIFIC
                    TABLE 302 ROAPAC: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                    TABLE 303 ROAPAC: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 304 ROAPAC: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 305 ROAPAC: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                    TABLE 306 ROAPAC: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
    9.5 LATIN AMERICA
           TABLE 307 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           TABLE 308 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
           TABLE 309 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
           TABLE 310 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
           TABLE 311 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
           TABLE 312 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.5.1 BRAZIL
                    9.5.1.1 Growth of vaccine manufacturing to increase the market growth
                               TABLE 313 BRAZIL: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                               TABLE 314 BRAZIL: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 315 BRAZIL: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 316 BRAZIL: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                               TABLE 317 BRAZIL: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.5.2 ROLATAM
                    TABLE 318 ROLATAM: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                    TABLE 319 ROLATAM: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 320 ROLATAM: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 321 ROLATAM: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                    TABLE 322 ROLATAM: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
    9.6 MIDDLE EAST & AFRICA
           TABLE 323 HEMOPHILIA PATIENTS IN THE MIDDLE EAST & AFRICA, BY COUNTRY, 2012–2020
           TABLE 324 PER CAPITA CONSUMPTION OF FACTORS IX AND VIII (IU/TOTAL POPULATION) IN SOUTH AFRICA, SAUDI ARABIA, AND IRAQ, 2012–2018
           TABLE 325 MEA: PLASMA FRACTIONATION MARKET, BY COUNTRY,  2020–2027 (USD MILLION)
           TABLE 326 MEA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
           TABLE 327 MEA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
           TABLE 328 MEA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
           TABLE 329 MEA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
           TABLE 330 MEA: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.6.1 TURKEY
                    9.6.1.1 Turkey dominates the plasma fractionation market in the Middle East & Africa
                               TABLE 331 TURKEY: DEMOGRAPHIC INDICATORS
                               TABLE 332 TURKEY: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                               TABLE 333 TURKEY: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 334 TURKEY: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 335 TURKEY: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                               TABLE 336 TURKEY: PLASMA FRACTIONATION MARKET, BY END USER,  2020–2027 (USD MILLION)
           9.6.2 SAUDI ARABIA
                    9.6.2.1 Developments in healthcare infrastructure to support market growth
                               TABLE 337 SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                               TABLE 338 SAUDI ARABIA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 339 SAUDI ARABIA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 340 SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                               TABLE 341 SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.6.3 EGYPT
                    9.6.3.1 Growing research on plasma and plasma derivatives will support market growth
                               TABLE 342 EGYPT: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                               TABLE 343 EGYPT: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 344 EGYPT: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 345 EGYPT: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                               TABLE 346 EGYPT: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.6.4 UAE
                    9.6.4.1 Growing government initiatives for healthcare infrastructure development to drive market growth in the UAE
                               TABLE 347 UAE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                               TABLE 348 UAE: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 349 UAE: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 350 UAE: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                               TABLE 351 UAE: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.6.5 REST OF THE MIDDLE EAST & AFRICA
                    TABLE 352 HEMOPHILIA PATIENTS IN THE REST OF MIDDLE EAST & AFRICA, 2012−2018
                    TABLE 353 ROMEA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                    TABLE 354 ROMEA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 355 ROMEA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 356 ROMEA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                    TABLE 357 ROMEA: PLASMA FRACTIONATION MARKET, BY END USER, 2020–2027 (USD MILLION)

10 COMPETITIVE LANDSCAPE (Page No. - 239)
     10.1 OVERVIEW
     10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
               FIGURE 30 KEY PLAYER STRATEGIES IN THE PLASMA FRACTIONATION MARKET, 2018–2022
     10.3 MARKET SHARE ANALYSIS
               FIGURE 31 PLASMA FRACTIONATION MARKET: MARKET SHARE ANALYSIS, 2021 (TOP 5 PLAYERS)
               TABLE 358 PLASMA FRACTIONATION MARKET: DEGREE OF COMPETITION
     10.4 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS
               FIGURE 32 REVENUE SHARE ANALYSIS OF PLAYERS IN THE PLASMA FRACTIONATION MARKET (TOP 5)
     10.5 COMPANY EVALUATION QUADRANT
             10.5.1 STARS
             10.5.2 EMERGING LEADERS
             10.5.3 PERVASIVE PLAYERS
             10.5.4 PARTICIPANTS
                       FIGURE 33 PLASMA FRACTIONATION MARKET: COMPANY EVALUATION QUADRANT, 2021
     10.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES
             10.6.1 PROGRESSIVE COMPANIES
             10.6.2 STARTING BLOCKS
             10.6.3 RESPONSIVE COMPANIES
             10.6.4 DYNAMIC COMPANIES
                       FIGURE 34 PLASMA FRACTIONATION MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2021
     10.7 COMPETITIVE BENCHMARKING
             10.7.1 COMPANY PRODUCT & REGIONAL FOOTPRINT (25 COMPANIES)
                       FIGURE 35 PRODUCT & REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE PLASMA FRACTIONATION MARKET
             10.7.2 COMPANY PRODUCT FOOTPRINT (25 COMPANIES)
                       TABLE 359 PRODUCT PORTFOLIO ANALYSIS: PLASMA FRACTIONATION MARKET (2021)
             10.7.3 COMPANY REGIONAL FOOTPRINT (25 COMPANIES)
                       TABLE 360 REGIONAL REVENUE MIX: PLASMA FRACTIONATION MARKET (2021)
     10.8 COMPETITIVE SCENARIO AND TRENDS
               TABLE 361 PRODUCT LAUNCHES & APPROVALS, JANUARY 2018–APRIL 2022
               TABLE 362 DEALS, JANUARY 2018–APRIL 2022
               TABLE 363 OTHER DEVELOPMENTS, JANUARY 2018–APRIL 2022
     10.9 COMPETITIVE BENCHMARKING
               TABLE 364 PLASMA FRACTIONATION MARKET: DETAILED LIST OF KEY START-UPS/SMES
               TABLE 365 PLASMA FRACTIONATION MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS [START-UPS/SMES]

11 COMPANY PROFILES (Page No. - 256)
     11.1 KEY PLAYERS
(Business overview, Products offered, Recent Developments, MNM view)*
             11.1.1 CSL
                       TABLE 366 CSL: BUSINESS OVERVIEW
                       FIGURE 36 CSL: COMPANY SNAPSHOT (2021)
             11.1.2 GRIFOLS, S.A.
                       TABLE 367 GRIFOLS, S.A.: BUSINESS OVERVIEW
                       FIGURE 37 GRIFOLS, S.A.: COMPANY SNAPSHOT (2021)
             11.1.3 SHIRE (TAKEDA PHARMACEUTICAL COMPANY LIMITED)
                       TABLE 368 SHIRE: BUSINESS OVERVIEW
                       FIGURE 38 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2021)
             11.1.4 OCTAPHARMA AG
                       TABLE 369 OCTAPHARMA AG: BUSINESS OVERVIEW
                       FIGURE 39 OCTAPHARMA AG: COMPANY SNAPSHOT (2021)
             11.1.5 KEDRION S.P.A
                       TABLE 370 KEDRION S.P.A: BUSINESS OVERVIEW
                       FIGURE 40 KEDRION S.P.A: COMPANY SNAPSHOT (2020)
             11.1.6 LFB
                       TABLE 371 LFB: BUSINESS OVERVIEW
             11.1.7 BIOTEST AG
                       TABLE 372 BIOTEST AG: BUSINESS OVERVIEW
                       FIGURE 41 BIOTEST AG: COMPANY SNAPSHOT (2021)
             11.1.8 SANQUIN
                       TABLE 373 SANQUIN: BUSINESS OVERVIEW
                       FIGURE 42 SANQUIN: COMPANY SNAPSHOT (2021)
             11.1.9 CHINA BIOLOGIC PRODUCTS HOLDINGS, INC.
                       TABLE 374 CHINA BIOLOGIC PRODUCTS HOLDINGS, INC.: BUSINESS OVERVIEW
             11.1.10 GC PHARMA
                       TABLE 375 GC PHARMA: BUSINESS OVERVIEW
                       FIGURE 43 GC PHARMA: COMPANY SNAPSHOT (2020)
             11.1.11 BIO PRODUCTS LABORATORY LTD.
                       TABLE 376 BIO PRODUCTS LABORATORY LTD.: BUSINESS OVERVIEW
             11.1.12 JAPAN BLOOD PRODUCTS ORGANIZATION
                       TABLE 377 JAPAN BLOOD PRODUCTS ORGANIZATION: BUSINESS OVERVIEW
                       FIGURE 44 JAPAN BLOOD PRODUCTS ORGANIZATION: COMPANY SNAPSHOT (2020)
             11.1.13 EMERGENT BIOSOLUTIONS
                       TABLE 378 EMERGENT BIOSOLUTIONS: BUSINESS OVERVIEW
                       FIGURE 45 EMERGENT BIOSOLUTIONS: COMPANY SNAPSHOT (2021)
             11.1.14 SHANGHAI RAAS BLOOD PRODUCTS CO., LTD.
                       TABLE 379 SHANGHAI RAAS BLOOD PRODUCTS CO., LTD.: BUSINESS OVERVIEW
             11.1.15 INTAS PHARMACEUTICALS LTD.
                       TABLE 380 INTAS PHARMACEUTICALS LTD.: BUSINESS OVERVIEW
                       FIGURE 46 INTAS PHARMACEUTICALS LTD.: COMPANY SNAPSHOT (2021)
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
     11.2 OTHER COMPANIES
             11.2.1 BHARAT SERUMS AND VACCINES LIMITED
             11.2.2 SK PLASMA
             11.2.3 SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO., LTD.
             11.2.4 KABAFUSION
             11.2.5 CENTURION PHARMA
             11.2.6 ADMA BIOLOGICS, INC.
             11.2.7 PLASMAGEN BIOSCIENCES PVT. LTD.
             11.2.8 VIRCHOW BIOTECH PRIVATE LIMITED
             11.2.9 FUSION HEALTHCARE
             11.2.10 HEMARUS THERAPEUTICS LIMITED

12 APPENDIX (Page No. - 319)
     12.1 DISCUSSION GUIDE
     12.2 AVAILABLE CUSTOMIZATIONS
     12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     12.4 RELATED REPORTS
     12.5 AUTHOR DETAILS

This study involved four major activities in estimating the current size of the plasma fractionation market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the plasma fractionation market. The secondary sources used for this study include International Plasma Fractionation Association (IPFA), Plasma Protein Therapeutics Association (PPTA), International Plasma Products Industry Association (IPPIA), European Association of the Plasma Products Industry (EAPPI), World Health Organization (WHO), Annual Reports, SEC Filings, Investor Presentations, Expert Interviews, and MarketsandMarkets Analysis. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

Plasma Fractionation Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the plasma fractionation market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and market have been identified through extensive secondary research
  • The revenues generated from the plasma fractionation business of leading players have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Data Triangulation

After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Report Objectives

  • To define, describe, and forecast the global plasma fractionation market based on the product, application, end user and region
  • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, challenges, and opportunities)
  • To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall plasma fractionation market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa
  • To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and R&D activities in the plasma fractionation market.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Company Information

  • An additional five company profiles
Report Code
BT 3042
Published ON
May, 2022
Choose License Type
BUY NOW
GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

SEND ME A FREE SAMPLE
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2022 MarketsandMarkets Research Private Ltd. All rights reserved